Alcohol Use Disorder
Conditions
Keywords
retina AND electroretinogram
Brief summary
Alcohol is a major public health problem and its neurotoxic effects are, among other things, responsible for altering the functioning of cerebral neurotransmission pathways. The retina is an anatomical and developmental extension of the central nervous system. It is composed of several layers of retinal neurons that share similar anatomical and functional properties with brain neurons. Retinal neurons are notably equipped with a complex system of neurotransmission constituted by the main neurotransmitters that are involved in the central effects of alcohol: glutamate, dopamine, serotonin ... The retina is used here as a site of indirect investigation for abnormal central neurotransmission pathways following regular alcohol use. It is recognized to date as a good site for investigating central abnormalities in neuropsychiatric and addictive disorders. The objective of this project is to study the retinal function using electroretinogram (ERG) in regular alcohol users to isolate potential markers of cerebral neurotransmission abnormalities.
Interventions
OTHERelectroretinogram (flash, pattern and multifocal)
we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
Sponsors
Centre Psychothérapique de Nancy
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
mono centric study, in parallel groups, controlled, non-randomized and open
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
For alcohol consumer with alcohol use disorder : Inclusion Criteria: * aged between 18 and 35 years * alcohol use disorder according to the DSM 5 * affiliation to a social security scheme
Exclusion criteria
* psychoactive substance consumption (other than alcohol) * psychiatric disease in progress according to the DSM 5 * neurologic disease in progress * mental impairment making it difficult or impossible to participate to the study * major under guardianship or curatorship or under safeguarding of justice * pregnant women or feeding * people in emergency situation * participation to another interventional study * retinal disease in progress * chronic glaucoma * ophtalmic disease affecting the visual acuity * ocular infection in progress * urinary positive drug check the day of the inclusion * postive Breathalyser the day of the inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| modification of amplitude | Day 0 (=day of inclusion = the only visit of the study) | measured with flash electroretinogram and pattern electroretinogram / amplitude in microvolt |
| modification of implicite time parameters | Day 0 (=day of inclusion = the only visit of the study) | measured with flash electroretinogram and pattern electroretinogram - implicite time in millisecond |
| modification of amplitude of the oscillatory potential | Day 0 (=day of inclusion = the only visit of the study) | waves P1, P2, P3, P4 measured with flash electroretinogram - amplitude in microvolt |
| modification of implicit time of the oscillatory potential | Day 0 (=day of inclusion = the only visit of the study) | waves P1, P2, P3, P4 measured with flash electroretinogram - implicite time in millisecond |
| modification of amplitude of the background noise | Day 0 (=day of inclusion = the only visit of the study) | measured with the flash electroretinogram, flicker 3.0 sequence - amplitude in microvolt |
Countries
France
Outcome results
None listed